CLINICAL TRIALS PROFILE FOR CYSTADROPS
✉ Email this page to a colleague
All Clinical Trials for CYSTADROPS
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT04125927 ↗ | Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2) | Recruiting | Recordati Rare Diseases | Phase 3 | 2020-09-01 | Cystadrops® is currently indicated in adults and children from 2 years of age diagnosed with cystinosis with corneal crystal accumulation observed. However administration of Cystadrops® in patients below 2 years old could be of value for these patients and prevent the crystal deposit. It is the reason why as part of the Cystadrops® pediatric investigational plan (PIP), RECORDATI Rare Diseases committed to conduct a clinical study to assess Cystadrops® safety and efficacy in the pediatric population from 6 months to less than 2 years old. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CYSTADROPS
Condition Name
Clinical Trial Locations for CYSTADROPS
Clinical Trial Progress for CYSTADROPS
Clinical Trial Phase
Clinical Trial Sponsors for CYSTADROPS
Sponsor Name